MedTrace Logo

Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study

NCT02033434 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-09-26

No results posted yet for this study

Summary

The investigators hypothesize that intra-nasal ketamine, for analgesia of patients with moderate to severe pain in an alpine setting, will provide a clinically significant reduction in pain and provide an effective and feasible alternative to intravenous opioids.

The investigators wish to know:

1. Is our study protocol feasible to study INK in a mountain, prehospital care environment?
2. What estimate can be made of recruitment rates?
3. Does studying the use of INK interfere with or delay care at Whistler/Blackcomb?
4. Is intra-nasal ketamine an effective and safe method for controlling pain in our study population and setting?
5. Does intranasal ketamine provide a clinically significant reduction in pain or do patients require additional IV narcotics for extraction?
6. Are there any significant changes in vital signs after administration of intra-nasal ketamine
7. Does the use of intra-nasal ketamine reduce time of patient extraction and transport in the alpine pre-hospital setting?
8. Are there any long term sequelae of INK at one week?

Conditions

  • Pain
  • Traumatic Limb Injury

Interventions

DRUG

Intranasal Ketamine

Atomized Intranasal Ketamine, 50mg

Sponsors & Collaborators

  • University of British Columbia

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Gary Andolfatto, MD · University of British Columbia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-01
Primary Completion
2016-05-15
Completion
2017-09-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02033434 on ClinicalTrials.gov